Idera, BioCryst to merge, fortifying their position in rare disease

With the rare disease landscape heating up, the two companies will meld their pipelines and management to find a better footing.

By Jacob Bell • Jan. 22, 2018

Sanofi beefs up pipeline with $11B Bioverativ buy

The French pharma is adding a hemophilia franchise and strengthening its rare disease portfolio in a much-needed acquisition. 

By Lisa LaMotta • Jan. 22, 2018

Celgene buys Juno for $9B, deepening bet on CAR-T

Acquiring Juno will pit Celgene against Novartis and fellow large-cap biotech Gilead in the rapidly emerging field of cell therapy.

By Ned Pagliarulo • Jan. 22, 2018

Prescribed Reading: Murmurs of M&A, backlash over CRLs

Celgene may make another acquisition, while the FDA Commissioner gets his first negative marks for reneging on a promise. 

By Lisa LaMotta • Jan. 19, 2018

US health systems set up generic non-profit

In a move to cut shortages and stem price hikes, four health systems and the VA are creating their own generic drug company.

By Suzanne Elvidge • Jan. 19, 2018

Sandoz taps Biocon for biosimilar deal

The companies will collaborate on copycat biologics for cancer and immunology. 

By Lisa LaMotta • Jan. 18, 2018

Report: Small deals aren't the answer to big pharma's woes

Drugmakers turned to less pricey — and less risky — M&A in 2017, but a new report outlines why such deals won't solve industry-wide issues.

By Jacob Bell • Jan. 18, 2018

Post-review, Aeterna Zentaris strikes commercialization deal

After a complicated year including a strategic review, Quebecois company Aeterna Zentaris inks a small deal to help it move forward. 

By Suzanne Elvidge • Jan. 18, 2018

Boehringer, hot on deals, adds another with Adimab collaboration

A new deal gives the German drugmaker access to antibodies against a range of targets.

By Suzanne Elvidge • Jan. 12, 2018

JPM18: No mega-deals for Lilly, Ricks says

A Lilly SVP for business development also updated BioPharma Dive on areas of focus. 

By Lisa LaMotta • Jan. 11, 2018

JPM18 Day 3: Valeant and Acorda make plans, promises of M&A

Attendees were a bit more pessimistic during the last full day of the J.P. Morgan Healthcare Conference, but a few biotech CEOs still brimmed with confidence.

By Ned Pagliarulo , Lisa LaMotta • Jan. 10, 2018

JPM18 Day 2: Roche on gene therapy, Aimmune nears key readout and outpatient CAR-T

No new billion-dollar deals were announced on the second day of the J.P. Morgan meeting. Yet investors appeared more optimistic, pushing biotech shares up.

By Ned Pagliarulo , Lisa LaMotta • Jan. 9, 2018

Teva, Alder ink migraine deal to avoid legal headache

Locked in a heated race to market, the companies agreed to exchange cash for a patent license so both could move forward.

By Jacob Bell • Jan. 9, 2018

JPM18: Alnylam and Sanofi reshuffle rare disease RNAi deal

The new agreement restores Alnylam's rights to its ATTR amyloidosis portfolio, as well as opens potential income streams.

By Suzanne Elvidge • Jan. 9, 2018

JPM18: Regeneron, Sanofi boost I/O investment

The closely knit pair upped their investment in their immuno-oncology candidate, extending a partnership.

By Lisa LaMotta • Jan. 8, 2018

Novo Nordisk puts $3B on the table for Ablynx

The Danish drugmaker's latest offer is 14% higher than its first, but Ablynx remains unimpressed.

By Jacob Bell • Jan. 8, 2018

Celgene aims to quell growth worries with $7B Impact deal

Buying Impact Biomedicines will give Celgene an NDA-ready blood disease drug to bolster a pipeline shaken by a recent setback.

By Ned Pagliarulo • Jan. 7, 2018

Taxes, tech and China to fuel pharma M&A in 2018, says EY

Repatriated cash coupled with growing competitive threats will leave the market 'ripe' for more life sciences deals, according to a new report.

By Jacob Bell • Jan. 7, 2018

With TiGenix buy and Denali deal, Takeda shows its hand

The Japan-based pharma has been eager to expand its global footprint, and two new agreements should help reinforce its presence in Europe and the U.S.

By Jacob Bell • Jan. 5, 2018

In surprise move, Pfizer hands back IDO1 inhibitor

iTeos Therapeutics has regained rights to its Phase 1 brain cancer drug from Pfizer, and plans to continue oncology development.

By Suzanne Elvidge • Jan. 5, 2018

MacroGenics finds new pharma partner in Roche

After being stung by J&J's recent decision to drop a clinical candidate, Macrogenics has lined up another early-stage collaboration deal. 

By Ned Pagliarulo • Jan. 4, 2018

Pfizer targets harmful proteins in $830M deal

A research collaboration between the big pharma and Arvinas will focus on discovering therapies for disease-causing cellular proteins.

By Jacob Bell • Jan. 4, 2018

Indivior adds to addiction pipeline with Addex deal

The UK biotech takes on another addiction treatment after losing patent protection for its lead drug. 

By Lisa LaMotta • Jan. 3, 2018

Top 10 stories that had pharma execs talking

From CAR-T to potential deals, BioPharma readers dove into these pieces.

By Lisa LaMotta • Jan. 3, 2018

AstraZeneca sells US rights to 4 non-core drugs

Continuing its externalization drive, the British drugmaker stands to receive nearly $50 million for handing over several licenses and NDAs to ANI Pharmaceuticals.

By Jacob Bell • Jan. 2, 2018